Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Aug 17;17(8):e0272663. doi: 10.1371/journal.pone.0272663

Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: A prospective longitudinal study

Elsa Lorthe 1,*,#, Mathilde Bellon 2,3,#, Grégoire Michielin 4, Julie Berthelot 1, María-Eugenia Zaballa 1, Francesco Pennacchio 1, Meriem Bekliz 2, Florian Laubscher 5, Fatemeh Arefi 4, Javier Perez-Saez 1,6, Andrew S Azman 1,6,7, Arnaud G L’Huillier 5,8, Klara M Posfay-Barbe 8, Laurent Kaiser 3,9, Idris Guessous 10,11, Sebastian J Maerkl 4, Isabella Eckerle 2,3,5,9,, Silvia Stringhini 1,11,12,; on behalf of the SEROCoV-Schools Study Group
Editor: Debdutta Bhattacharya13
PMCID: PMC9385020  PMID: 35976947

Abstract

Objectives

To report a prospective epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak in a primary school.

Methods

As part of a longitudinal, prospective, school-based surveillance study, this investigation involved repeated testing of 73 pupils, 9 teachers, 13 non-teaching staff and 26 household members of participants who tested positive, with rapid antigen tests and/or RT-PCR (Day 0–2 and Day 5–7), serologies on dried capillary blood samples (Day 0–2 and Day 30), contact tracing interviews and SARS-CoV-2 whole genome sequencing.

Results

We identified 20 children (aged 4 to 6 years from 4 school classes), 2 teachers and a total of 4 household members who were infected by the Alpha variant during this outbreak. Infection attack rates were between 11.8 and 62.0% among pupils from the 4 school classes, 22.2% among teachers and 0% among non-teaching staff. Secondary attack rate among household members was 15.4%. Symptoms were reported by 63% of infected children, 100% of teachers and 50% of household members. All analysed sequences but one showed 100% identity. Serological tests detected 8 seroconversions unidentified by SARS-CoV-2 virological tests.

Conclusions

This study confirmed child-to-child and child-to-adult SARS-CoV-2 transmission and introduction into households. Effective measures to limit transmission in schools have the potential to reduce the overall community circulation.

Introduction

Children play an important role in the transmission of many respiratory viral diseases, including beta-coronaviruses and influenza virus, both within schools [1] and within households [2, 3]. This has led most countries worldwide to implement school closures as one component of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission mitigation policies from the very beginning of the pandemic [4].

Young children commonly have fewer and milder symptoms of SARS-CoV-2 infection than adults, with a high proportion of asymptomatic infections, and are less likely to experience severe coronavirus disease (COVID-19) [5]. However, epidemiological and biological data suggest that, when infected, children transmit as much as adults, as children achieve viral loads comparable, or only minimally lower, to those of adults at the time of diagnosis [610].

At school, young children have many prolonged close contacts with peers and adults indoors [11], usually do not wear masks, and in many countries they are not systematically tested when symptomatic, including in Switzerland [12]. These circumstances make children and schools a potential strong contributor of the overall community SARS-CoV-2 transmission [13]. Published studies reported school outbreaks in the United States [1416], Australia [17], England [18], Ireland [19], Norway [20] or Italy [21], and/or seroprevalence estimates in schools in Switzerland [22, 23], Canada [24] or Germany [25, 26]. Overall, they suggested a relatively low incidence of COVID-19 in children or low prevalence of anti-SARS-CoV-2 antibodies, conveying the message that schools are not a high risk setting for transmission of COVID-19 [27, 28]. However, most studies were retrospective, had limited participation rates, were performed before the emergence of variants of concern, and did not systematically test both symptomatic and asymptomatic children and adults. Therefore, the extent to which young children are infected and transmit SARS-CoV-2 in school settings remains controversial [5, 29, 30], in particular with variants of concern. Evidence on transmission direction (adult-to-child, child-to-child, child-to-adult) is also sparse.

We aim to report a prospective epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak in a primary school in Geneva, Switzerland, in April-May 2021.

Materials and methods

Study design

This outbreak investigation is part of a longitudinal, prospective, surveillance study (SEROCoV-Schools), which aims to describe the transmission dynamics of SARS-CoV-2 infection within primary schools and early childhood education centres in a sample of five institutions in Geneva, and the risk of introduction of SARS-CoV-2 into the children’s households. The study started in March 2021. Participants (pupils and their teachers) had a baseline assessment which included SARS-CoV-2 serology from a capillary blood test, an antigen rapid diagnostic test (RDT) from an oropharyngeal swab sample, and the completion of an online questionnaire. Then, a surveillance phase started, with weekly questionnaires and self-declarations (anytime outside of the weekly questionnaires) allowing participants to report COVID-19-like symptoms, contact with a positive case or the diagnosis of a SARS-CoV-2 infection. An outbreak investigation was triggered when a positive case was diagnosed from a positive real-time reverse transcription polymerase chain reaction (RT-PCR), which was the case on April 26, 2021. The date of diagnosis of the first positive case in a school class was referred to as Day 0 for that school class. The investigation involved repeated virological and serological testing of the participants: RDT and/or RT-PCR were performed at Day 0–2 and Day 5–7, serologies were performed at Day 0–2 and Day 30.

Study population

In the investigated school, all 9 school classes with children aged 3 to 6–7 years old participated in the SEROCoV-Schools study. The present study population consisted of children and school staff in school classes with a positive case as well as household members of the confirmed cases. School staff included teachers (including assistants) and non-teaching staff (administrative, cleaners, catering). Two children in Class 2 were absent from school for the 2 weeks preceding this outbreak, therefore they were considered as non-exposed and not included in the analysis.

Context and public health measures

During the period of this outbreak investigation, non-pharmaceutical public health measures in Geneva were gradually relaxed, with restaurants and bars opening their outdoor spaces and entertainment venues opening their indoor spaces.

Mitigation of the COVID-19 pandemic in Switzerland included school closures during the first wave from March to May 2020. Thereafter, priority was given to keeping schools open with several types of preventive measures in place which varied widely across institutions. In the investigated school, measures in place during the outbreak included checking children’s temperature every morning, sending children home if they had fever or sickness beyond very mild symptoms, restricted access for parents and requiring all adults (but not young children) to wear facemasks.

Epidemiological investigation

Case definition

Cases were defined according to laboratory results: confirmed SARS-CoV-2-infected cases were those with positive SARS-CoV-2 RDT and/or RT-PCR results, and/or a seroconversion between Day 0–2 and Day 30 (from seronegative to seropositive according to the test-specific cut-off, unrelated to vaccination). Confirmed cases could be further classified as symptomatic or asymptomatic.

Outcomes

Only descriptive analyses are presented here. Infection attack rates (IAR) were defined as the number of children and school staff with a positive RDT and/or RT-PCR detected within a 21-day period of the index case identification, and/or a seroconversion, divided by the total number of children and school staff participating in the study. Household secondary attack rates (SAR) were defined as the number of non-index household members who tested positive by RDT and/or RT-PCR within a 21-day period of the first infection detected in each household or who seroconverted, divided by the total number of non-index members participating in the study. Adults were defined as individuals ≥18 years, whereas children were defined as individuals <18 years of age. Plausible directions of transmission were determined, when possible, on the basis of symptom onset and testing dates.

Contact tracing

Positive cases (or their parents in the case of children) were interviewed using a structured questionnaire investigating symptoms, contact with a positive person, school attendance, extracurricular activities, play dates/birthday parties, family/friend gatherings and best friends, in the 14 days prior to diagnosis.

Laboratory investigation

Virological testing

SARS-CoV-2 testing was performed on oropharyngeal swabs taken by nurses or medical doctors of the study team. This swabbing method is less invasive than nasopharyngeal swabs and more acceptable by young children. Children who were not attending school on the testing days were tested by their paediatrician or at a testing centre and communicated the results to our team. Depending on the visit, we performed RT-PCR or RDT tests. We used the Panbio COVID-19 Ag rapid test (Abbott) which has been validated in adults for use with oropharyngeal instead of nasopharyngeal swabs [31]. All oropharyngeal swab samples used for the RDT were tested a second time from the same swab by RT-PCR to confirm the result (in-house SARS-CoV-2 RT-qPCR or Cobas® SARS-CoV-2 Test, Cobas 6800, Roche, Switzerland). SARS-CoV-2 whole genome sequencing was performed for positive samples at the Health 2030 Genome Center (Geneva) using the Illumina COVIDSeq library preparation reagents following the protocol provided by the supplier. All results were communicated to the participants as soon as they became available.

Serological testing

We collected capillary blood on a Neoteryx Mitra® collection device at Day 0–2 and Day 30, and tested for anti-Spike-SARS-CoV-2 IgG on a microfluidic nanoimmunoassay as described previously [32]. This sampling method is minimally invasive, easily implementable in schools and more acceptable than traditional venipuncture by children. Serologies were communicated to the families approximately 2 months after the visit.

Ethics

This study was approved by the ethics committee of the Canton of Geneva (Project ID 2020–02957). All parents and teachers were informed about the study (orally and through a flyer and a detailed information note) and gave written consent. We also provided a short letter written in a child-friendly style, and a schema illustrating concepts of infection and antibodies, which parents could use to inform their child. Before each test, a team of trained nurses discussed with each child, explained the tests to be taken and answered any questions. Children gave verbal assent to participate.

Results

Outbreak description, epidemiological and serological investigation

The first COVID-19 case (index case: Teacher 1 [T1], Class 1) was diagnosed by RT-PCR performed in a laboratory on April 26, 2021 (Fig 1), 3 days after the onset of symptoms (April 23). This participant reported the result to our team, which triggered the investigation. The second teacher in Class 1 (T2) had symptoms onset on April 24 with an initially negative RT-PCR on April 26 followed by a positive RT-PCR on April 28 (Fig 2). Both attended school until April 23 included.

Fig 1. Epidemic curve of cases confirmed by positive RDT or RT-PCR (n = 15), school outbreak, Geneva, Switzerland, 2021.

Fig 1

Apr: April.

Fig 2. Timeline of symptoms onset, diagnosis and virological analyses among cases with a confirmed SARS-CoV-2 infection (positive RDT, RT-PCR or seroconversion).

Fig 2

Apr: April, HAx: Adult member of household, HCx: Child member of household, Jun: June, Kx: Kid x, Tx: Teacher x, RDT: antigen rapid diagnostic test, RT-PCR: real-time reverse transcription polymerase chain reaction.

All 21 children from Class 1, aged 4 years old, were tested on April 27, 2021. They all attended school the week before. The IAR was 62% (13/21): 1 child had a positive RDT confirmed by a RT-PCR (Kid 1 [K1]); 5 children had a negative RDT, but subsequent RT-PCR testing on the same swab samples came back positive (K2, K3, K8, K11, K12); 2 children absent from school because symptomatic were tested by healthcare providers outside the study setting, both had a positive RT-PCR (K4, K5); 1 child had a positive RT-PCR at the second visit at Day 7 (K10); and 4 children seroconverted between the first and the last visit at D30 (K13, K14, K15, K16) despite negative swab virological tests at Day 1 and Day 7 (Table 1, Figs 13).

Table 1. Overview of tests results, symptoms and cases among the 4 investigated classes, teachers and non-teaching staff.

Visit 1 (Day 0–2) Visit 2 (Day 5–7)a Seroconversion (D30)b Symptomsc Total casesd
RDT + n positive/n tested RT-PCR + n positive/n tested RDT + n positive/n tested RT-PCR + n positive/n tested n seroconversions/N tested n/n confirmed cases n confirmed cases/n tested
Class A 1/17 8e/21 0/1 1/16 4/11 10/13 13/21
Class B -/- 2/17 -/- 0/15 0/12 1/2 2/19
Class C 0/1 1/17 0/14 0/2 2/16f 0/3 3/18
Class D -/- 0/15 0/12 0/1 2/10 1/2g 2/15
Teachers 0/4 2/9 0/2 0/3 0/7 2/2 2/9
Non-teaching staff 0/2 0/10 0/4 0/2 0/10 -/- 0/13

a Tests were not repeated in participants with a SARS-CoV-2 infection diagnosed at Visit 1

b Among participants with negative swab tests both at Visit 1 and Visit 2, and negative serology at baseline and/or at Visit 1. Adults who were vaccinated and developed antibodies between visit 1 and visit 3 were not considered as related to the outbreak.

c Among participants with a SARS-CoV-2 positive test and/or a seroconversion

d A case was defined as a participant with a positive RDT and/or a positive RT-PCR and/or a seroconversion.

e Including confirmation of one positive RDT by a subsequent RT-PCR performed on the same day

f Including 1 seroconversion between March 26, 2021 and May 11, 2021

g No data on symptoms for one child

Fig 3. Results of serological tests at baseline, at D0-2 and D30 for all pupils, teachers, non-teaching staff and household members included in the outbreak investigation.

Fig 3

This figure displays the results of the serological tests performed at baseline (black square), i.e. at the beginning of the study in March 2021, and during the outbreak investigation at Day 0–2 (blue circle) and Day 30 (red diamond). Adults who were vaccinated during the outbreak investigation are indicated by a yellow diamond. Household members who had no serological test are not represented. D: Day, HAx: Adult member of household, HCx: Child member of household, Kx: Kid x, Tx: Teacher x, PCR: real-time reverse transcription polymerase chain reaction.

Children in another school class from the same grade (Class 2) were identified as having close contacts with children of Class 1 during breaks and specific activities. Class 2 was therefore tested on April 29, 2021. Of the 19 children aged 4 years old, 17 were tested by RT-PCR, of whom 2 (K6, K7) tested positive (IAR 11.8%), and 2 did not participate in the outbreak investigation (they both had only a negative RT-PCR performed externally on May 6). No additional case was identified at subsequent visits. We also repeatedly tested 4 teachers and 2 non-teaching staff in contact with Classes 1 and 2, none of whom was diagnosed with a SARS-CoV-2 infection (Table 1).

Of note, all children from these two school classes were placed in quarantine by local health authorities for 10 days from April 30, 2021.

The sibling of a positive case from Class 1, attending Class 3 in the same school, tested positive on May 2 (K9), triggering the testing protocol in Class 3. All 17 6-year old tested in Class 3 had a negative RT-PCR on May 4, and 16/16 had a negative RDT on May 11 (subsequently confirmed with a RT-PCR). Serological tests at Day 30 revealed 2 additional seroconversions (K17, K20, of whom one was not tested at Day 2 of the outbreak but seroconverted since baseline at the end of March 2021) (IAR 16.7%). In the other school class from the same grade, Class 4, tested because of close and regular contacts with Class 3, 15/15 had a negative RT-PCR on May 4, 13/13 had a negative RDT on May 11, and 2 additional cases of seroconversion (K18, K19) were identified (IAR 13.3%); 2 children in the school class did not take part in the study (Table 1, Fig 2). Among 3 teachers and 11 non-teaching staff, none tested positive.

Transmission occurred in 3 out of 10 investigated households of participants with a positive SARS-CoV-2 test, leading to a secondary attack rate among household members of 4/26 (15.4%). Three members of the same household refused to participate in this investigation, two of whom were vaccinated. Secondary attack rates were 1/2 (50.0%) with an adult index case, and 3/24 (12.5%) with a child index case. A teacher spent a few days at his/her parents’ place while having symptoms, his/her parent then developed symptoms and tested positive (adult household member [HA17]). The parent (HA5) of a positive child from Class 1 tested negative twice (RDT on May 1, RT-PCR on May 7), though he/she seroconverted (Figs 2 and 3). He/she reported no contacts outside his/her household, strictly followed all recommendations, and was not vaccinated between the two blood draws. Finally, in the family of two children from Classes 1 and 3 who tested positive one after the other, a parent (HA1) who initially tested negative by RT-PCR, tested positive after quarantine with his/her children.

Among the 15 cases with a positive SARS-CoV-2 test, 3/3 (100%) adults and 9/12 (69%) children reported symptoms either before or after the positive test, and 3 children were asymptomatic. Among the 8 children who seroconverted without a positive RDT or RT-PCR test, 3 were symptomatic, 4 were asymptomatic, and one did not provide symptom information. Overall, 12/19 (63%) infected children reported symptoms. No severe form of COVID-19 (requiring hospitalization) was reported, and all cases recovered well.

Contact tracing analysis

The two infected teachers live alone and reported no contact with a positive or symptomatic case in their private life or activities, during the 14 days prior to infection. Their presumed source of infection was school, as several children from Class 1 were coughing during the week of April 19. The two infected parents were likely infected by their children, as they reported no contact outside the household.

Three social activities outside the school setting occurred in the two weeks before the triggering case was diagnosed: the first one (April 18, outdoors) brought together 6 children from Class 1 of whom 5 subsequently tested positive and 3 kids from another school (not included in the study); the second one (April 21, both indoors and outdoors) gathered 4 children from Class 1 and Class 2 of whom 3 tested positive (the other one had antibodies at baseline and at Visit 1); the last one (April 24, outdoors) was attended by 2 kids from Class 1 and 2 kids from another school (not included in the study), 1 tested positive at the 2nd visit.

Virological investigation

We conducted whole genome sequencing on samples from the 15 participants who tested positive for SARS-CoV-2. Coverage of three isolate genomes (HA1, K9 and K10) were insufficient for any comparisons due to low viral load in the specimen (32%, 20% and 16% coverage only, respectively). The other sequenced genomes belonged to the Alpha variant. The virus sequence of K12 differed from the others in one region covered. Here, in position 15824–15827 a deletion and one addition that restores the reading frame was observed, resulting in a total of 4 nucleotides difference compared to the other sequences. All 9 sequences with >99% coverage shared 100% identity between genomes in comparison to the reference sequence (Fig 4). Virus specimens that could only be partially sequenced retrieved the same sequence without additional mutations in the regions covered.

Fig 4. Virological analysis of positive cases by SARS-CoV-2 full genome sequencing.

Fig 4

Mutations in comparison to the reference sequence (NC_045512) are highlighted in orange. Green fields indicate no mutation; grey fields indicate insufficient genome coverage; and yellow fields indicate mixed viral population of the two nucleotides given. Numbers indicate nucleotide positions; asterisks (*) mark lineage-defining mutations for the Alpha variant. ID: Identifier, GISAID: Global Initiative on Sharing Avian Influenza Data, Kx: Kid x, Tx: Teacher x.

Discussion

This is one of the first investigation of a SARS-CoV-2 outbreak caused by the Alpha variant in a primary school. It involved 20 children from 4 school classes, 2 teachers and 4 household members (of whom one triggered the investigation in another school class). The primary case could not be formally identified, but it is likely that this outbreak started during the week of April 19 and was only identified on April 26 when a teacher tested positive and triggered the investigation. Of note, children in this age group were not routinely tested by the official testing recommendations in Switzerland when symptomatic [12]. This prospective school class-based study provides evidence of SARS-CoV-2 circulation among young children, school teachers, and introduction into households.

Since at least 9 positive cases of this outbreak shared viruses with identical sequence, we conclude that they are part of the same cluster. This could have been either by simultaneous infection through the same source, or transmission chains between affected individuals. One divergent virus sequence was found in one of the positive children, which could be either a de novo mutation occurring during the outbreak, or constitute independent introductions into the school, with one leading to this cluster. It cannot be ruled out that, by coincidence, several infection events with viruses sharing the same sequence were introduced from the community independently into the school. However, this hypothesis seems less likely given the number of cases involved, the epidemiological link and time frame, and the limited period of potentially other exposures before the quarantine decision. Overall community circulation at the cantonal level was also relatively low at the time (weekly incidence: about 200 cases/100,000 inhabitants). Between April 15 and May 15, the Alpha variant was causing 92% of new SARS-CoV-2 infections in Geneva [33].

Other main insights are as follows. First, viral circulation of the Alpha variant in young children aged 4–6 years old was high, with a majority of unspecific and mild symptomatic infections, which might explain relatively high secondary attack rates [13]. The observed cluster probably started in one class and spread to two other classes, most likely through direct child-to-child contacts and interactions as per our epidemiological investigation, although there could be non-sampled child or adult intermediaries. We identified two seroconversions in a fourth class, but with no identification of SARS-CoV-2 virus, thereby limiting the conclusions on transmission linked to the other school classes. Similar patterns were found in a prospective study of three B.1.1.7 variant outbreaks which occurred in three childcare centers in Germany in January–February 2021: 11/12 groups had secondary cases, and secondary attack rates ranged from 7 to 64% among groups of children aged 1–6 years [34].

Second, child-to-parent transmission occurred in two different households, and child-to-teacher transmission is probable, which supports previous findings [18, 3436]. Of note, vaccination was opened to all persons aged 45 years or older from April 12, and to all people in the 16–44 age group from May 19. Therefore, only a minority of adults (1 household member and 1 non-teaching staff) were vaccinated at the beginning of the outbreak. Child-to-adult transmission seems to depend on the duration of contacts, as no infection was identified among non-teaching staff who spent only limited periods of time (meals) with children. This is contrary to previous findings [37], and may be explained by the young age of our participants and their behaviour involving physical proximity with their teachers [38].

Third, social activities outside the school could have contributed to the spread of the infection, as previously reported [39, 40]. However, they could also reflect the bonding between children and a closer contact at school, thus facilitating transmission.

Fourth, we evidenced low sensitivity of RDTs with an oropharyngeal specimen for identifying both symptomatic and asymptomatic infected children, which confirms previous results showing that only children with high viral load are identified by such tests [23, 41]. We conclude that RDTs with an oropharyngeal specimen are not the most appropriate for surveillance and/or outbreak investigation purposes. The analysis of joint RT-PCR/serological data shows a substantial under-detection of infections in young children, even with RT-PCR testing, although the optimal time point for viral testing might have been missed in the fixed testing scheme of this study. This finding is consistent with prospective research based on comprehensive testing protocols which identified a higher incidence of COVID-19 among children and higher rates of transmission than previously reported, including in households [14, 35, 36]. Under-detection of acutely infected children may be an explanation for the discrepancy between official numbers of infected children [42] and studies on virus prevalence and seroprevalence in school settings [24, 28, 4347].

As a take-home message, we suggest that routinely reported infections are likely to be just the tip of the iceberg, highlighting the importance of testing contacts, regardless of symptoms, to identify SARS-CoV-2 infections and stop transmission by rapidly isolating positive cases.

Strengths and limitations

Few large SARS-CoV-2 outbreaks in young children in school settings have been documented so far [48, 49] even fewer involved an investigation of variants of concern. As part of an ongoing prospective study, this investigation started less than 24 hours after the first case was laboratory-confirmed and involved the use of three complementary approaches. We followed up and repeatedly tested all contacts within four school classes regardless of symptoms. Repeated serological tests proved useful to retrieve seroconversions following asymptomatic or undiagnosed infections. However, we relied on a limited number of cases, even though, by definition, the sample size of a school class outbreak can only be as large as the number of pupils in each school class. Not all children and adults were tested, which could lead to underestimating IAR and SAR. We might have missed infections among adults who were vaccinated between Day 0–2 and Day 30, as we could not distinguish between antibodies due to vaccination and those due to infection. Also, we could not test the household members of cases only detected by seroconversion at Day 30 with no positive RT-PCR/RDT, leading to a potential underestimation of secondary attack rates. The study was performed before the circulation of the more infectious Delta and Omicron variants; estimates are therefore likely to be underestimated [5053].

Conclusion

This prospective school-based study provides evidence of SARS-CoV-2 transmission among young children and school teachers and introduction into households. Epidemiological investigation confirmed child-to-child and child-to-adult direction of transmission of the infection. Children may be a significant source of extra-household infections and have the potential to play a role in community transmission, potentially even more so with more contagious variants. With most of the adult and adolescent population vaccinated, young children could act as disease reservoirs. Effective strategies are needed to limit transmission in school settings and vaccination of school staff and children should be encouraged.

Acknowledgments

We are very grateful to the children and teachers participating in the SEROCoV-Schools study and their families. We would like to thank the school staff for their responsiveness and support during the outbreak investigation. The authors also would like to thank the members of the Unit of Population Epidemiology for their daily support in all the tasks required by the SEROCoV-School study and the Virology Laboratory staff for performing RT-PCRs and for helping with the storage of the samples.

SEROCoV-Schools Study Group:

Elsa Lorthe (lead author, elsa.lorthe@gmail.com, Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Julie Berthelot (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Maria-Eugenia Zaballa (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Hélène Baysson (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland), Andrea Jutta Loizeau (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Ania Wisniak (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland), Stéphanie Testini (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Khadija Samir (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Natalie Francioli (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Severine Harnal (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Deborah Urrutia Rivas (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Javier Perez-Saez (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA), Nick Pullen (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Francesco Pennacchio (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Julien Lamour (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Richard Dubos (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Gaëlle Bryand-Rumley (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Claire Semaani (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Viviane Richard (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Roxane Dumont (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Prune Collombet (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland), Natacha Noël (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Patrick Bleich (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Nacira El Merjani (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Caroline Pugin (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Jessica Rizzo (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Marion Frangville (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Antoine Bal (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Fanny-Blanche Lombard (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Zo Francia Randrianandrasana (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Oumar Aly Ba (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Chantal Martinez (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Paola D’Ippolito (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Camille Tible (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Viola Bucolli (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Livia Boehm (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Adrien Jos Rastello (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland), Lucie Ménard (Médecine & Hygiène, 1225 Chêne-Bourg), Lison Beigbeder (Médecine & Hygiène, 1225 Chêne-Bourg), Fréderic Rinaldi (dotBase, 1227 Geneva), Alain Cudet (dotBase, 1227 Geneva), Alexandre Moulin (dotBase, 1227 Geneva), Andrew S Azman (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA), Arnaud G L’Huillier (Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland; Department of Pediatrics, Gynecology & Obstetrics, Pediatric Infectious Disease Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland), Klara M Posfay-Barbe (Department of Pediatrics, Gynecology & Obstetrics, Pediatric Infectious Disease Unit, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland), Idris Guessous (Division of Primary Care, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland), Silvia Stringhini (Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland; Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; University Center for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland), Grégoire Michielin (Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland), Sebastian J Maerkl (Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland), Fatemeh Arefi (Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland), Mathilde Bellon (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Isabella Eckerle (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland; Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland), Laurent Kaiser (Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland; Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland), Benjamin Meyer (Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland), Meriem Bekliz (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Florian Laubscher (Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland), Francisco Perez Rodriguez (Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Pascale Sattonnet-Roche (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Catia Alvarez (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Kenneth Adea (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Manel Essaidi-Laziosi (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland), Gil Barbosa Monteiro (Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland)

Data Availability

Despite all the precautions taken, our data contain potentially identifying information due to the nature of this study and the fact that we are reporting information on relatively small groups of children from a specific geographic location. Therefore, the study steering committee members decided to make these data accessible to researchers who meet the criteria for access to confidential data upon reasonable request for data sharing to the Unit of Population Epidemiology (uep@hcuge.ch). All requests will be evaluated by the Data Access Committee and approved on the basis of their scientific quality.

Funding Statement

Funding: The SEROCoV-Schools study was supported by the Federal Office of Public Health, the Private Foundation of the Geneva University Hospitals, the Fondation des Grangettes, the Center for Emerging Viral Diseases, and a SNF NRP (National Research Program) 78 Covid-19 Grant 198412 (to S.J.M., I.E.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Marchbanks TL, Bhattarai A, Fagan RP, Ostroff S, Sodha SV, Moll ME, et al. An Outbreak of 2009 Pandemic Influenza A (H1N1) Virus Infection in an Elementary School in Pennsylvania. Clin Infect Dis. 2011;52(Suppl 1):S154‑60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cauchemez S, Donnelly CA, Reed C, Ghani AC, Fraser C, Kent CK, et al. Household Transmission of 2009 Pandemic Influenza A (H1N1) Virus in the United States. New England Journal of Medicine. 2009;361(27):2619‑27. doi: 10.1056/NEJMoa0905498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, et al. Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of Households in Michigan. J Infect Dis. 2020;222(1):9‑16. doi: 10.1093/infdis/jiaa161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Viner RM, Russell SJ, Croker H, Packer J, Ward J, Stansfield C, et al. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child Adolesc Health. 2020;4(5):397‑404. doi: 10.1016/S2352-4642(20)30095-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wiedenmann M, Goutaki M, Keiser O, Stringhini S, Tanner M, Low N. The role of children and adolescents in the SARS-CoV-2 pandemic: a rapid review. Swiss Med Wkly. 2021. Sep 17;151:w30058 doi: 10.4414/smw.2021.w30058 [DOI] [PubMed] [Google Scholar]
  • 6.Zhu Y, Bloxham CJ, Hulme KD, Sinclair JE, Tong ZWM, Steele LE, et al. A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. Clinical Infectious Diseases. 2021;72(12):e1146‑53. doi: 10.1093/cid/ciaa1825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373(6551):eabi5273. doi: 10.1126/science.abi5273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Baggio S, L’Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. SARS-CoV-2 viral load in the upper respiratory tract of children and adults with early acute COVID-19. Clin Infect Dis. 2020;ciaa1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.L’Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis. 2020;26(10):2494‑7. doi: 10.3201/eid2610.202403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bellon M, Baggio S, Bausch FJ, Spechbach H, Salamun J, Genecand C, et al. SARS-CoV-2 viral load kinetics in symptomatic children, adolescents and adults. Clin Infect Dis. 2021;ciab396. doi: 10.1093/cid/ciab396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Stehlé J, Voirin N, Barrat A, Cattuto C, Isella L, Pinton JF, et al. High-Resolution Measurements of Face-to-Face Contact Patterns in a Primary School. PLoS One. 2011;6(8):e23176. doi: 10.1371/journal.pone.0023176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.BAG. COVID-19—Recommandations sur la procédure à suivre pour les enfants symptomatiques de moins de 6 ans ainsi que les autres personnes fréquentant les écoles et les structures d’accueil parascolaire/extrafamilial et indications de test chez les enfants de moins de 6 ans [Internet]. 2021. Disponible sur: https://cdn.paediatrieschweiz.ch/production/uploads/2021/03/2021.03.23-Indications-de-test-chez-les-enfants-symptomatiques-de-moins-de-6-ans.pdf
  • 13.Cevik M, Marcus JL, Buckee C, Smith TC. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics Should Inform Policy. Clinical Infectious Diseases. 2021;73(Supplement_2):S170‑6. doi: 10.1093/cid/ciaa1442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Gettings JR, Gold JAW, Kimball A, Forsberg K, Scott C, Uehara A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District—United States, December 2020–January 2021. Clinical Infectious Diseases. 2022;74(2):319‑26. doi: 10.1093/cid/ciab332 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Dawson P, Worrell MC, Malone S, Tinker SC, Fritz S, Maricque B, et al. Pilot Investigation of SARS-CoV-2 Secondary Transmission in Kindergarten Through Grade 12 Schools Implementing Mitigation Strategies—St. Louis County and City of Springfield, Missouri, December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(12):449‑55. doi: 10.15585/mmwr.mm7012e4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hershow RB, Wu K, Lewis NM, Milne AT, Currie D, Smith AR, et al. Low SARS-CoV-2 Transmission in Elementary Schools—Salt Lake County, Utah, December 3, 2020-January 31, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(12):442‑8. doi: 10.15585/mmwr.mm7012e3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. The Lancet Child & Adolescent Health. 2020;4(11):807‑16. doi: 10.1016/S2352-4642(20)30251-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ismail SA, Saliba V, Bernal JL, Ramsay ME, Ladhani SN. SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England. The Lancet Infectious Diseases. 2021;21(3):344‑53. doi: 10.1016/S1473-3099(20)30882-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. Euro Surveill. 2020;25(21). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Brandal LT, Ofitserova TS, Meijerink H, Rykkvin R, Lund HM, Hungnes O, et al. Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020. Eurosurveillance. 2021;26(1):2002011. doi: 10.2807/1560-7917.ES.2020.26.1.2002011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Larosa E, Djuric O, Cassinadri M, Cilloni S, Bisaccia E, Vicentini M, et al. Secondary transmission of COVID-19 in preschool and school settings in northern Italy after their reopening in September 2020: a population-based study. Eurosurveillance. 2020;25(49):2001911. doi: 10.2807/1560-7917.ES.2020.25.49.2001911 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ulyte A, Radtke T, Abela IA, Haile SR, Blankenberger J, Jung R, et al. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland. BMJ Open. 2021;11(7):e047483. doi: 10.1136/bmjopen-2020-047483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kriemler S, Ulyte A, Ammann P, Peralta GP, Berger C, Puhan MA, et al. Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland. Front Pediatr. 2021;9:645577. doi: 10.3389/fped.2021.645577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zinszer K, McKinnon B, Bourque N, Pierce L, Saucier A, Otis A, et al. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. JAMA Network Open. 2021;4(11):e2135975. doi: 10.1001/jamanetworkopen.2021.35975 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Theuring S, Thielecke M, Loon W van, Hommes F, Hülso C, Haar A von der, et al. SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020. Eurosurveillance. 2021;26(34):2100184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Katz SE, McHenry R, Mauer LG, Chappell JD, Stewart LS, Schmitz JE, et al. Low In-School COVID-19 Transmission and Asymptomatic Infection Despite High Community Prevalence. The Journal of Pediatrics. 2021;237:302–306.e1. doi: 10.1016/j.jpeds.2021.06.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Alonso S, Català M, López D, Álvarez-Lacalle E, Jordan I, García-García JJ, et al. Individual prevention and containment measures in schools in Catalonia, Spain, and community transmission of SARS-CoV-2 after school re-opening. PLoS One. 2022;17(2):e0263741. doi: 10.1371/journal.pone.0263741 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hommes F, van Loon W, Thielecke M, Abramovich I, Lieber S, Hammerich R, et al. SARS-CoV-2 Infection, Risk Perception, Behaviour, and Preventive Measures at Schools in Berlin, Germany, during the Early Post-Lockdown Phase: A Cross-Sectional Study. Int J Environ Res Public Health. 2021;18(5):2739. doi: 10.3390/ijerph18052739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Yung CF, Kam K qian, Nadua KD, Chong CY, Tan NWH, Li J, et al. Novel Coronavirus 2019 Transmission Risk in Educational Settings. Clinical Infectious Diseases. 2021;72(6):1055‑8. doi: 10.1093/cid/ciaa794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Viner R, Waddington C, Mytton O, Booy R, Cruz J, Ward J, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: A meta-analysis of population-based and contact-tracing studies. J Infect. 2021;S0163-4453(21)00633-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nsoga MTN, Kronig I, Rodriguez FJP, Sattonnet-Roche P, Silva DD, Helbling J, et al. Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2. PLOS ONE. 2021;16(6):e0253321. doi: 10.1371/journal.pone.0253321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Swank Z, Michielin G, Yip HM, Cohen P, Andrey DO, Vuilleumier N, et al. A high-throughput microfluidic nanoimmunoassay for detecting anti–SARS-CoV-2 antibodies in serum or ultralow-volume blood samples. Proc Natl Acad Sci U S A. 2021. May 4;118(18):e2025289118. doi: 10.1073/pnas.2025289118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Althaus CL, Baggio S, Reichmuth ML, Hodcroft EB, Riou J, Neher RA, et al. A tale of two variants: Spread of SARS-CoV-2 variants Alpha in Geneva, Switzerland, and Beta in South Africa [Internet]. medRxiv 2021.06.10.21258468 [Google Scholar]
  • 34.Loenenbach A, Markus I, Lehfeld AS, Heiden M an der, Haas W, Kiegele M, et al. SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021. Eurosurveillance. 2021;26(21):2100433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Meuris C, Kremer C, Geerinck A, Locquet M, Bruyère O, Defêche J, et al. Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Liège, Belgium. JAMA Network Open. 2021;4(10):e2128757. doi: 10.1001/jamanetworkopen.2021.28757 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Kolodziej LM, van Lelyveld SFL, Haverkort ME, Mariman R, Sluiter-Post JGC, Badoux P, et al. High Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission Rates Detected by Dense Saliva Sampling. Clinical Infectious Diseases. 2022;ciac261. doi: 10.1093/cid/ciac261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ladhani SN, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, et al. SARS-CoV-2 infection and transmission in primary schools in England in June–December, 2020 (sKIDs): an active, prospective surveillance study. The Lancet Child & Adolescent Health. 2021;5(6):417‑27. doi: 10.1016/S2352-4642(21)00061-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Paul LA, Daneman N, Schwartz KL, Science M, Brown KA, Whelan M, et al. Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. JAMA Pediatr. 2021;175(11):1151–1158. doi: 10.1001/jamapediatrics.2021.2770 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ghinai I, Woods S, Ritger KA, McPherson TD, Black SR, Sparrow L, et al. Community Transmission of SARS-CoV-2 at Two Family Gatherings—Chicago, Illinois, February–March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):446‑50. doi: 10.15585/mmwr.mm6915e1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Naimark D, Mishra S, Barrett K, Khan YA, Mac S, Ximenes R, et al. Simulation-Based Estimation of SARS-CoV-2 Infections Associated With School Closures and Community-Based Nonpharmaceutical Interventions in Ontario, Canada. JAMA Network Open. 2021;4(3):e213793. doi: 10.1001/jamanetworkopen.2021.3793 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.L’Huillier AG, Lacour M, Sadiku D, Gadiri MA, De Siebenthal L, Schibler M, et al. Diagnostic Accuracy of SARS-CoV-2 Rapid Antigen Detection Testing in Symptomatic and Asymptomatic Children in the Clinical Setting. J Clin Microbiol. 2021;59(9):e0099121. doi: 10.1128/JCM.00991-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Posfay-Barbe KM, Andrey DO, Virzi J, Cohen P, Pigny F, Goncalves AR, et al. Prevalence of IgG against SARS-CoV-2 and evaluation of a rapid MEDsan IgG test in children seeking medical care. Clin Infect Dis. 2020;ciaa1702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Villani A, Coltella L, Ranno S, Bianchi di Castelbianco F, Murru PM, Sonnino R, et al. School in Italy: a safe place for children and adolescents. Ital J Pediatr. 2021;47:23. doi: 10.1186/s13052-021-00978-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Varma JK, Thamkittikasem J, Whittemore K, Alexander M, Stephens DH, Arslanian K, et al. COVID-19 Infections Among Students and Staff in New York City Public Schools. Pediatrics. 2021;147(5):e2021050605. doi: 10.1542/peds.2021-050605 [DOI] [PubMed] [Google Scholar]
  • 45.Fontanet A, Tondeur L, Grant R, Temmam S, Madec Y, Bigot T, et al. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020. Eurosurveillance. 2021;26(15):2001695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Dattner I, Goldberg Y, Katriel G, Yaari R, Gal N, Miron Y, et al. The role of children in the spread of COVID-19: Using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. PLoS Comput Biol. 2021;17(2):e1008559. doi: 10.1371/journal.pcbi.1008559 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ulyte A, Radtke T, Abela IA, Haile SR, Ammann P, Berger C, et al. Evolution of SARS-CoV-2 seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona. Swiss Med Wkly. 2021;151:w30092. doi: 10.4414/smw.2021.w30092 [DOI] [PubMed] [Google Scholar]
  • 48.Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, et al. A large COVID-19 outbreak in a high school 10 days after schools’ reopening, Israel, May 2020. Eurosurveillance. 2020;25(29):2001352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Torres JP, Piñera C, De La Maza V, Lagomarcino AJ, Simian D, Torres B, et al. SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study. Clin Infect Dis. 2020;ciaa955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Li B, Deng A, Li K, Hu Y, Li Z, Xiong Q, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nat Commun. 2022;13(1):460. doi: 10.1038/s41467-022-28089-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Lorthe E, Bellon M, Berthelot J, Michielin G, L’Huillier AG, Posfay-Barbe KM, et al. A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland. Lancet Infect Dis. 2022;S1473-3099(22)00267-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Head JR, Andrejko KL, Remais JV. Model-based assessment of SARS-CoV-2 Delta variant transmission dynamics within partially vaccinated K-12 school populations. Lancet Reg Health Am. 2022;5:100133. doi: 10.1016/j.lana.2021.100133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Lam-Hine T, McCurdy SA, Santora L, Duncan L, Corbett-Detig R, Kapusinszky B, et al. Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School—Marin County, California, May–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(35):1214‑9. doi: 10.15585/mmwr.mm7035e2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Binod Kumar

3 May 2022

PONE-D-22-07591Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal studyPLOS ONE

Dear Dr. Lorthe,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. 

Please submit your revised manuscript by Jun 16 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Binod Kumar, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. One of the noted authors is a group or consortium the SEROCoV-Schools Study Group. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

4. Please ensure that you refer to Figure 4 in your text as, if accepted, production will need this reference to link the reader to the figure.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the present prospective study titled “Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal study” the author tried to address the transmission of SARS-CoV-2 from school to households. This study investigated SARS-CoV-2 outbreak in a primary school in Geneva, Switzerland in the months of April and May in the year 2021. The study is well designed and describes the transmission dynamics of SARS-CoV-2 from school children to households. They used well established diagnostic protocols such as rapid antigen test, RT-PCR, serological anti-spike antibodies and Viral genome sequencing for the identification and tracing infection.

The only limitation to this study is the sample size which the author also agreed in their discussion. However, this kind of study’s are important in implementing effective strategies to limit the transmission.

Reviewer #2: This manuscript upholds children and schools as a potential strong contributor of the overall community SARS-CoV-2 transmission which is highly relevant as many Lockdown protocols suspended schools or switched to remote learning.

Minor comments:

The results and conclusions are too short. There is no information on peak infectivity period of open cases. How long the student/teacher were at school before symptoms appear i.e. was there asymptomatic spread and if any signs or symptoms were subjects quarantined or home isolated (did subjects attend school while waiting for the tests). During contact tracing was it all suspected contact transmission, droplets or aerosol transmission? Authors do mention “quarantine by local health authorities for 10 days” does that apply to the whole class together or different individuals according to SARS-CoV-2 positivity/visible clinical symptoms?

Authors need to describe abbreviations whenever used for the first time including obvious D0-1.

Major comments:

The term “verbal consent” by children is confusing as children do not have the legal capacity to “consent” to participate in research. The proper terminology is “Ascent” which just needs paraphrasing as it is what researchers did. Authors may want to mention how the children were informed e.g. videos, graphics, and other visual aids to help explain the trial along with that fact that it is a minimal risk category trial.

Decision:

This is a very systematic and well laid out study. It’s unusual for going with fixed testing scheme for COVID-19 testing trials. Authors have explained the settings and limitations very well and leaves readers to compare their study findings. With so many studies published on alpha virus dynamics, the publication does seem dissociated as there is scarce literature review in both introduction as well as discussion sections.

With much more high transmission SARS-CoV-2 strains circulating and the rapid changes in the dynamics, public health is in continuous pressure and risky updates. It would be prudent if some take home message is added in context of current scenario from findings of this study.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ella Bhagyaraj

Reviewer #2: Yes: Yash Gupta

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 17;17(8):e0272663. doi: 10.1371/journal.pone.0272663.r002

Author response to Decision Letter 0


7 Jun 2022

Journal Requirements: When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

We have adapted our manuscript to meet PLOS ONE’s style requirements.

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

Despite all the precautions taken, our data contain potentially identifying information due to the nature of this study and the fact that we are reporting information on relatively small groups of children from a specific geographic location. Therefore, the study steering committee members decided to make these data accessible to researchers who meet the criteria for access to confidential data upon reasonable request for data sharing to the Unit of Population Epidemiology (uep@hcuge.ch). All requests will be evaluated by the Data Access Committee and approved on the basis of their scientific quality.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. One of the noted authors is a group or consortium the SEROCoV-Schools Study Group. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.

The lead author of the SEROCoV-Schools group has been mentioned in the group list, with an email address. All individual affiliations have been added in the acknowledgements section, as required.

4. Please ensure that you refer to Figure 4 in your text as, if accepted, production will need this reference to link the reader to the figure.

The reference to Figure 4 has been added in the manuscript.

5. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

We have checked the references list, and have updated a reference from a pre-print that is now published. We have also added references in response to the reviewer’s advice to provide a more extensive literature review.

Comments to the Author

Reviewer #1: In the present prospective study titled “Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal study” the author tried to address the transmission of SARS-CoV-2 from school to households. This study investigated SARS-CoV-2 outbreak in a primary school in Geneva, Switzerland in the months of April and May in the year 2021. The study is well designed and describes the transmission dynamics of SARS-CoV-2 from school children to households. They used well established diagnostic protocols such as rapid antigen test, RT-PCR, serological anti-spike antibodies and Viral genome sequencing for the identification and tracing infection. The only limitation to this study is the sample size which the author also agreed in their discussion. However, this kind of study’s are important in implementing effective strategies to limit the transmission.

We would like to thank the reviewer for this positive evaluation of our work. We acknowledge a limited sample size, however, by definition, the sample size of a school class outbreak can only be as large as the number of pupils in each school class. As participation was high, we were in the best possible conditions to study this outbreak.

Reviewer #2: This manuscript upholds children and schools as a potential strong contributor of the overall community SARS-CoV-2 transmission which is highly relevant as many Lockdown protocols suspended schools or switched to remote learning.

Minor comments:

The results and conclusions are too short.

We consider these two sections to be quite comprehensive. We welcome any suggestions for topics that should be covered further.

There is no information on peak infectivity period of open cases. How long the student/teacher were at school before symptoms appear i.e. was there asymptomatic spread and if any signs or symptoms were subjects quarantined or home isolated (did subjects attend school while waiting for the tests).

Unfortunately, the design of this study did not allow to estimate the peak infectivity period: once a participant tested positive, he/she was not retested at subsequent visits of the same infection. Peak infectivity, however, has been described in previous studies and seems to occur on the day of symptom onset or a few days before (https://doi.org/10.1038/s41591-020-0869-5). As mentioned in the article, 2 children were absent from school for 2 weeks prior to this outbreak and were not included in the investigation, while 2 symptomatic children were absent from school when we organized the first tests, both were tested by healthcare providers outside the study setting and had a positive RT-PCR. All other participants were attending school as usual. The first teacher who tested positive was at school on the Friday when symptoms started, but then stayed home until the positive test and 10 days afterwards. We added this information in the manuscript: “Both attended school until April 23 included.” and “They all attended school the week before.”.

As there were no specific recommendations from the health authorities at the outbreak onset, children attended school as usual before the tests (that we were able to organize very quickly after the first case was notified). Importantly, the results of the antigen rapid diagnostic tests performed by our team were available in 15 minutes, and were communicated immediately to the families. The results of the RT-PCR tests were communicated within 24 hours. Of course, all subjects who tested positive were home isolated for 10 days. Information on the communication of results was added in the manuscript: “All results were communicated to the participants as soon as they became available.”, “Serologies were communicated to the families approximately 2 months after the visit.”.

Therefore, asymptomatic spread likely happened.

During contact tracing was it all suspected contact transmission, droplets or aerosol transmission?

We did not aim to determine the mode of transmission (contact, droplets or aerosol) with this study. As a consequence, we did not focus our investigation and contact tracing interviews on this point. All we can say is that close contacts occurred both at school and at home, and that young children were not wearing face masks. This last information was added in the manuscript: “In the investigated school, measures in place during the outbreak included checking children’s temperature every morning, sending children home if they had fever or sickness beyond very mild symptoms, restricted access for parents and requiring all adults (but not young children) to wear facemasks.”

Authors do mention “quarantine by local health authorities for 10 days” does that apply to the whole class together or different individuals according to SARS-CoV-2 positivity/visible clinical symptoms?

The local health authorities decided to quarantine all children in these two classes for 10 days. We have clarified this point in the manuscript: “Of note, all children from these two classes were placed in quarantine by local health authorities for 10 days from April 30, 2021.”

Authors need to describe abbreviations whenever used for the first time including obvious D0-1.

We have removed all abbreviations related to Days for ease of reading.

Major comments:

The term “verbal consent” by children is confusing as children do not have the legal capacity to “consent” to participate in research. The proper terminology is “Ascent” which just needs paraphrasing as it is what researchers did.

Following the reviewer’s advice, we have replaced consent with assent.

Authors may want to mention how the children were informed e.g. videos, graphics, and other visual aids to help explain the trial along with that fact that it is a minimal risk category trial.

Teachers, school staff and parents were informed both orally and through a set of documents including a flyer and a detailed information note. We also provided a short letter written in a child-friendly style, and a schema illustrating the concepts of infection and antibodies, which parents could use to inform their child. Before each test, a team of trained nurses discussed with each child, explained the tests to be taken and answered any question children may have had. The test was then performed only if the child agreed it. Because most participants were very young children, we chose minimally invasive tests.

We have detailed these elements in the manuscript:

“All parents and teachers were informed about the study (orally and through a flyer and a detailed information note) and gave written consent. We also provided a short letter written in a child-friendly style, and a schema illustrating concepts of infection and antibodies, which parents could use to inform their child. Before each test, a team of trained nurses discussed with each child, explained the tests to be taken and answered any questions. Children gave verbal consent assent to participate.”

“This swabbing method is less invasive than nasopharyngeal swabs and more acceptable by young children.”

“This sampling method is minimally invasive, easily implementable in schools and more acceptable than traditional venipuncture by children.”

Decision:

This is a very systematic and well laid out study. It’s unusual for going with fixed testing scheme for COVID-19 testing trials. Authors have explained the settings and limitations very well and leaves readers to compare their study findings. With so many studies published on alpha virus dynamics, the publication does seem dissociated as there is scarce literature review in both introduction as well as discussion sections.

To respond to the concern raised by the reviewer, we have revised the introduction and discussion sections and have added relevant references:

“Published studies reported school outbreaks in the United States, Australia, England, Ireland, Norway or Italy, and/or seroprevalence estimates in schools in Switzerland, Canada or Germany. Overall, they suggested a relatively low incidence of COVID-19 in children or low prevalence of anti-SARS-CoV-2 antibodies, conveying the message that schools are not a high risk setting for transmission of COVID-19.”

“Similar patterns were found in a prospective study of three B.1.1.7 variant outbreaks which occurred in three childcare centers in Germany in January–February 2021: 11/12 groups had secondary cases, and secondary attack rates ranged from 7 to 64% among groups of children aged 1-6 years.”

“This finding is consistent with prospective research based on comprehensive testing protocols which identified a higher incidence of COVID-19 among children and higher rates of transmission than previously reported, including in households.”

With much more high transmission SARS-CoV-2 strains circulating and the rapid changes in the dynamics, public health is in continuous pressure and risky updates. It would be prudent if some take home message is added in context of current scenario from findings of this study.

Thank you for this relevant suggestion. We have added the following sentence at the end of the discussion: “As a take-home message, we suggest that routinely reported infections are likely to be just the tip of the iceberg, highlighting the importance of testing contacts, regardless of symptoms, to identify SARS-CoV-2 infections and stop transmission by rapidly isolating positive cases.”

Attachment

Submitted filename: Response to Reviewers_1.docx

Decision Letter 1

Debdutta Bhattacharya

7 Jul 2022

PONE-D-22-07591R1Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal studyPLOS ONE

Dear Dr. Lorthe,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR:Please revise the paper as per the minor recommendations by the reviewer.

Please submit your revised manuscript by Aug 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Debdutta Bhattacharya

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The author addressed my concerns and improved the manuscript based on the reviewers comments and incorporated the changes.

Reviewer #2: All comments have been reasonably and meticulously addressed.

The limitations of the study have been clearly updated.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Yash Gupta

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 17;17(8):e0272663. doi: 10.1371/journal.pone.0272663.r004

Author response to Decision Letter 1


22 Jul 2022

This is a re-submission of my R1 revision. I received an email on July 7 asking for additional revisions, but the reviewers were satisfied with R1 and did not recommend any further revisions, so none have been made. There was apparently a technical error when the academic editor submitted their decision.

Decision Letter 2

Debdutta Bhattacharya

25 Jul 2022

Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal study

PONE-D-22-07591R2

Dear Dr. Lorthe,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Debdutta Bhattacharya

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Debdutta Bhattacharya

8 Aug 2022

PONE-D-22-07591R2

Epidemiological, virological and serological investigation of a SARS-CoV-2 outbreak (Alpha variant) in a primary school: a prospective longitudinal study

Dear Dr. Lorthe:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Debdutta Bhattacharya

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers_1.docx

    Data Availability Statement

    Despite all the precautions taken, our data contain potentially identifying information due to the nature of this study and the fact that we are reporting information on relatively small groups of children from a specific geographic location. Therefore, the study steering committee members decided to make these data accessible to researchers who meet the criteria for access to confidential data upon reasonable request for data sharing to the Unit of Population Epidemiology (uep@hcuge.ch). All requests will be evaluated by the Data Access Committee and approved on the basis of their scientific quality.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES